Single agent versus combination chemotherapy for metastatic breast cancer
about
Bending the Cost Curve in Cancer CareCombination versus sequential single agent chemotherapy for metastatic breast cancerA Review of Systemic Treatment in Metastatic Triple-Negative Breast CancerDelaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerMoving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial designMeta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancerSystemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelinesLapatinib for treatment of advanced or metastasized breast cancer: systematic review.A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancerAdjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer.An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents.The Role of Combination Chemotherapy in the Treatment of Patients with Metastatic Breast Cancer.Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatmentA prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancerClinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?Metastatic Breast Cancer to the Common Bile Duct Presenting as Obstructive Jaundice.Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer.Targeting angiogenesis in metastatic breast cancerPhysician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician surveyEffect of the Botanical Compound LCS101 on Chemotherapy-Induced Symptoms in Patients with Breast Cancer: A Case Series ReportChemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview.A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisoneRecent advances of cocktail chemotherapy by combination drug delivery systems.Salvianolic acid B protects against myocardial damage caused by nanocarrier TiO2; and synergistic anti-breast carcinoma effect with curcumin via codelivery system of folic acid-targeted and polyethylene glycol-modified TiO2 nanoparticlesA randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN studyInterdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012.A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients.Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study.Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives.Combination of 125I brachytherapy and chemotherapy for unresectable recurrent breast cancer: A retrospective control study.Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.The role of aryl hydrocarbon receptor and crosstalk with estrogen receptor in response of breast cancer cells to the novel antitumor agents benzothiazoles and aminoflavone.A decade of progress in cancer researchAnalysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.
P2860
Q22248106-9C459753-B29F-4BD1-9D1C-E163FF8B63C1Q24234874-897429BD-83B9-45D1-AC74-63CA59509F7FQ26752846-E560B3D3-9F38-4546-80BE-5D1C1C2891B6Q26770482-D1C908F2-32CC-447A-9E35-5219CA91BBE0Q26830525-800C7561-FF32-453E-8858-C77D98C041FBQ26860469-24B62B6C-FA85-44B7-AB7C-EA723D6AE4ADQ28080469-A9FE3867-D907-4652-BB98-877B463B171AQ33532659-DFED6C12-DCDE-4268-8BD0-08F72599A485Q33577876-261EFB31-3F39-4D29-A9BA-72285A940957Q33765404-D84BF74A-D077-4A94-B9FB-F61536E91A8CQ33895284-7FE498F1-9980-4779-BBB5-C646142EB5D1Q34140051-64F76AE5-A435-40C6-BBD1-6B572182041CQ35558126-E1466022-20EC-467F-8D47-70754CD7ADD7Q35584817-0B755E04-C003-4330-9021-3B854AF5C504Q35599769-9C18415A-4DAA-4BD5-B5B0-84E670BF6ADEQ35815486-CD12D655-0FE8-41EA-A892-F684F361E114Q36028687-9E664B7E-EA54-48FF-93AB-D913A26CDE81Q36085860-4FD112E7-4923-4972-B8A9-569A66977E33Q36182795-5945B47D-3628-4EF3-B530-CD992001BC77Q36528355-9D6CF341-0236-477D-A5F9-7432FC682D2CQ36581141-757B72F5-95F4-478C-A4A2-28EA244F3C58Q36630732-88533D29-4693-46AF-8EE7-0CBBB9C294D0Q37048596-F2C585B2-1C07-447B-ACC8-8C6E3ED3BB6BQ37152795-27177E40-E85D-4280-9529-863CCCB59BAAQ37206908-8ECB6645-34F7-4ABB-B5DE-65704FCF751BQ37398335-06E12B98-3B94-429A-8443-08B875C8661CQ37575167-43630B00-7646-4CF6-9C03-2C0586A4713FQ37657782-6F99D4D8-520E-436C-88E1-5F063B88B318Q37690380-F3AAFFEA-66F9-4D0F-958F-F5E00A851D15Q38221330-88BF631E-144D-4CD7-8B0F-206E09E81DB3Q38245797-AE51E218-FCFA-40DE-924B-73BCC287542DQ38661921-88DED3FF-A8A9-4B49-93B2-69EF9C75CB3CQ38854876-980BDE6D-1B63-48F6-8E74-013020F14444Q39163915-1554F7CD-3C93-40F5-B169-CA493C11C26BQ39262493-A8B3C161-6B99-46E0-B3BD-C636024725E7Q39311633-786F1EC6-44B7-42D2-BBCF-5BC778463608Q40548074-BF7DDDA5-6F78-4C5B-8CB1-F44232A2671AQ42693952-61DA86D9-F965-4F49-A488-D3DC285F9374Q43068334-AD2B33C9-7639-4CE7-BE7E-964BE8D72817Q45899129-7B5C2F9E-D06B-4910-9653-4FDAD2B7DEAC
P2860
Single agent versus combination chemotherapy for metastatic breast cancer
description
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
article scientifique (publié 2009/04/15)
@fr
articolo scientifico (pubblicato il 2009/04/15)
@it
artigo científico (publicado na 2009/04/15)
@pt
artikull shkencor
@sq
artículu científicu espublizáu en 2009
@ast
scientific article (publication date: 15 April 2009)
@en
vedecký článok (publikovaný 2009/04/15)
@sk
videnskabelig artikel (udgivet 2009/04/15)
@da
name
Single agent versus combination chemotherapy for metastatic breast cancer
@ast
Single agent versus combination chemotherapy for metastatic breast cancer
@en
Single agent versus combination chemotherapy for metastatic breast cancer
@en-gb
Single agent versus combination chemotherapy for metastatic breast cancer
@nl
type
label
Single agent versus combination chemotherapy for metastatic breast cancer
@ast
Single agent versus combination chemotherapy for metastatic breast cancer
@en
Single agent versus combination chemotherapy for metastatic breast cancer
@en-gb
Single agent versus combination chemotherapy for metastatic breast cancer
@nl
prefLabel
Single agent versus combination chemotherapy for metastatic breast cancer
@ast
Single agent versus combination chemotherapy for metastatic breast cancer
@en
Single agent versus combination chemotherapy for metastatic breast cancer
@en-gb
Single agent versus combination chemotherapy for metastatic breast cancer
@nl
P2093
P2860
P50
P3181
P1476
Single agent versus combination chemotherapy for metastatic breast cancer
@en
P2093
Charlene E Thornton
Davina Ghersi
John Simes
Nicholas Wilcken
Sharon Parker
Sue Carrick
P2860
P304
P3181
P356
10.1002/14651858.CD003372.PUB3
P577
2009-04-15T00:00:00Z